

London Cancer Haematology Cancer Tumour Pathway Board Annual Report 2018-19

Introduction

The Haematology Cancer Tumour Pathway Board is a cancer specific board led by Ronjon Chakraverty, Tumour Pathway Director, with project management support from Sherrice Weekes who took over from Simon Evans, September 2018. Its membership includes representation from cancer professionals across the region and active participation from primary care and from patients.



Professor Ronjon Chakraverty, Pathway Director & Professor of Haematology and Cellular Immunotherapy at Royal Free

Achievements this year

In 2018 the board focused on publishing pan London Haematology guidelines which cover a range of blood cancers including leukaemia, lymphoma, plasma cell disorders and more. This is the first time haematology guidelines have been published to cover the whole of London and will help to make sure that all blood cancer patients in London receive the same world class care - from diagnosis to treatment.

The 11 guidelines were completed and published September 2018 and can be found on all three of London's Cancer Alliance websites. Each year the guidelines will be reviewed jointly by clinicians in order to update the documents in line with best practice using new national or international guidance.

"The new guidelines have been written to help clinicians across London follow clear, consistent and evidence-based referral pathways for patients with blood cancers. In doing so we will be able to provide more consistent approaches to treatment and reduce unwarranted variations in care, ultimately helping to improve patient outcomes." Ronjon Chakraverty

Another achievement has been the development of the Patient Experience Specification; an audit tool for Trusts which can be used to review their current patient information standards. The tool will help services determine whether they meet the standard set out in the specification and then highlight any resources that may be required to improve services.

The Patient Experience Specification was amended by a newly formed project group;

- Patient Representatives; Bianca O'Donnell, Gilly Angell, Jane Morris and Peter Bion
- CNS'; Charina Ocampo and Michaela Plucinski
- GP; Hassan Al-Hashimi

This specification was presented and signed off by the Haematology pathway board in February 2019. This year will see the pilot and potential roll out of the specification across the Trusts in North East and North Central London.

Our key achievements also included:

- Having continued sight of common breach report themes
- Completing the Myeloma Gateway C (GP education) module. This online education portal will help GPs recognise signs and symptoms for Myeloma.
- Having two haematology Multi-Disciplinary Teams agree to receive coaching in order to improve MDT working.

Patient representation

This year we have had two new patient representatives join the pathway board alongside our current representatives. This has allowed us to continue to keep the patient voice at the forefront of all we do.

Future plans

No	Objective	Owner	By
1	Pan London Haematology Guidelines; <ul style="list-style-type: none">- To arrange writing groups to edit and update the 11 Pan London Haematology guidelines.- To publish the 2nd iteration of the Pan London Haematology guidelines.	RC	November 2019
2	To commence planning with Anthony Nolan team in order to pilot and audit the patient experience specification at Trusts in the network	RC	December 2019
3	To continue to ensure roll out of Gateway C; Myeloma GP education module across the network	RC	October 2019
4	To continue to analyse and develop solutions for lymphoma breaches via the pathway board's lymphoma working group	WT	March 2020
5	MDT Improvement; results and learning from the MDT coaching programme to be shared and used to improve MDT working	WT / RA	September 2019

Acknowledgements

We would like to thank all the members of the Haematology Cancer Tumour Pathway Board for contributing their time to Tumour Pathway Board meetings and projects outside the meeting.

Particular thanks to our patient representatives, Bianca O'Donnell, Gilly Angell, Jane Morris and Peter Bion, who have generously given up their time to contribute.